Replies to post #1716 on Palatin Technologies Inc. (PTN)

[seasonedwell]

You can not look at Addyi and get a proper prospective....Just look at the other 2......To many concerns and obstacles with Addyi

Addyi, which was approved in late summer by the U.S. Food and Drug Administration (FDA), hit the market on Oct. 17. HSDD is defined as a persistent absence of sexual thoughts, fantasies, responsiveness and willingness to engage in sexual activity that causes personal or relationship distress and cannot be accounted for by another medical condition or substance. However, the number of women diagnosed with HSDD is rather small, Jonathan Schaffir, an ob/gyn at the Ohio State University Wexner Medical Center in Columbus, told Bloomberg. Schaffir, who helped run clinical tests on the drug before Sprout acquired it, told Bloomberg none of his patients have inquired about Addyi.

Although the female sex drug is not truly comparable to Pfizer Inc. (PFE)’s sexual enhancement blockbuster drug Viagra, that medication was prescribed more than 500,000 times in its first week, Bloomberg said. Viagra and Eli Lilly and Company (LLY)'s Cialis had combined revenue of nearly $4 billion in 2014. Unlike the drug’s oft-compared male counterpart Viagra, Addyi addresses desire, not performance. Another difference between male erectile dysfunction drugs, Addyi is a once-daily dose that takes some time before the patient begins to see a difference in sexual desire. In clinical